Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Business Segments — Clinical trials

Similar metrics at other companies

CareDx logo
CDNAReportable Segment — Research materials and clinical trials expense
$3.83M+20.7%
Rigel Pharmaceuticals logo
RIGLSingle reportable segment — Outside clinical trial related expenses
$6.93M+58.5%
Recursion Pharmaceuticals, Inc. logo
RXRXReportable Segment — Clinical development
$10.67M-10.8%
Avalo Therapeutics logo
AVTXReportable Segment — Clinical expenses
$3.71M-48.6%
Vir Biotechnology, Inc. logo
VIRReportable Segment — Clinical costs
$22.53M+10.7%
TOI
TOIClinical trials & other — Total segment amortization
$0-100%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inbx:ResearchAndDevelopmentExpenseClinicalTrials.

The source filing: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026.

Filed
Mar 19, 2026, 4:00 PM EDT
Fiscal year
FY2025
Accession
0002007919-26-000006
Line itemYEAR ENDEDDECEMBER 31, 2025YEAR ENDEDDECEMBER 31, 2024
Revenue$1,300$200
Research and development expense
Personnel35,37272,790
Clinical trials35,33947,665
Contract manufacturing19,59055,643
Equipment, depreciation, and facility10,2279,693
Other research and development12,50017,952
General and administrative expense

Item 8. Financial Statements and Supplementary Data.

FAQ

What is Inhibrx Biosciences, Inc.'s business segments — clinical trials?
Inhibrx Biosciences, Inc. (INBX) reported business segments — clinical trials of $8.83M in Q4 2025.
How has Inhibrx Biosciences, Inc.'s business segments — clinical trials changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — clinical trials decreased by 25.9% year-over-year, from $11.92M to $8.83M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — clinical trials?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — clinical trials has grown at a -9.3% compound annual growth rate (CAGR), from $42.96M to $35.34M.
What does business segments — clinical trials mean?
Captures the direct costs incurred for conducting clinical studies and trials for the segment's therapeutic candidates. It is a critical indicator of the company's investment in advancing its pipeline through regulatory development phases.

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — clinical trials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude